Four Flavonols Show Multi-Target Power Against Alzheimer's Pathology
Quercetin, kaempferol, myricetin, and fisetin each attack Alzheimer's through distinct molecular pathways, from amyloid clearance to neuroinflammation.
Summary
A 2025 review in Biofactors examines how four plant-derived flavonols — quercetin, kaempferol, myricetin, and fisetin — combat Alzheimer's disease through complementary mechanisms. Each compound targets amyloid-β aggregation, oxidative stress, and neuroinflammation via distinct signaling pathways. Quercetin activates TrkB signaling and reduces tau phosphorylation; kaempferol blocks amyloid-induced apoptosis and inhibits acetylcholinesterase; myricetin improves mitochondrial function via GSK3β/ERK2 modulation; and fisetin boosts neprilysin to clear amyloid plaques. All four cross the blood-brain barrier with low toxicity, positioning them as promising multi-mechanistic candidates for clinical development in Alzheimer's treatment.
Detailed Summary
Alzheimer's disease (AD) remains one of the most devastating and treatment-resistant neurodegenerative conditions worldwide. Its complexity — driven by amyloid-β plaques, tau tangles, oxidative damage, and chronic neuroinflammation — has frustrated single-target drug strategies. Researchers are increasingly turning to natural polyphenols that can simultaneously address multiple disease pathways.
This 2025 review published in Biofactors systematically evaluates the therapeutic potential of four flavonols — quercetin, kaempferol, myricetin, and fisetin — against the core pathological hallmarks of AD. The authors synthesized preclinical and mechanistic evidence to map how each compound engages distinct molecular targets relevant to disease progression.
Key findings show that all four flavonols inhibit amyloid-β oligomerization and fibril formation while reducing oxidative stress through Nrf2/HO-1 pathway activation. They also suppress neuroinflammation by modulating microglial polarization. Quercetin stood out for activating TrkB signaling, reducing tau phosphorylation, and enhancing synaptic plasticity. Kaempferol prevented amyloid-induced apoptosis via ER/ERK/MAPK signaling and inhibited acetylcholinesterase, potentially improving cognition. Myricetin addressed mitochondrial dysfunction through GSK3β/ERK2 modulation, with nanostructured lipid carriers shown to improve its brain bioavailability. Fisetin reduced amyloid burden by upregulating neprilysin, a key amyloid-degrading enzyme, and restored synaptic protein levels.
The implications are significant: these compounds offer a multi-mechanistic approach that mirrors the complexity of AD pathology. Their ability to cross the blood-brain barrier and favorable safety profiles make them attractive candidates for clinical trials, either as standalone agents or adjuncts to existing therapies.
Important caveats apply. This is a review based primarily on preclinical data, and human clinical evidence remains limited. Bioavailability challenges and optimal dosing in humans have not been fully resolved, despite promising nanoformulation strategies.
Key Findings
- All four flavonols inhibit amyloid-β aggregation and activate Nrf2/HO-1 antioxidant pathways.
- Quercetin reduces tau phosphorylation and enhances synaptic plasticity via TrkB signaling.
- Kaempferol blocks amyloid-induced apoptosis and inhibits acetylcholinesterase to support cognition.
- Fisetin upregulates neprilysin, promoting enzymatic clearance of amyloid-β plaques.
- Myricetin delivered via nanostructured lipid carriers shows enhanced brain bioavailability.
Methodology
This is a narrative review synthesizing preclinical, in vitro, and in vivo mechanistic studies on four flavonols in the context of Alzheimer's disease. No original experimental data were generated; conclusions are drawn from existing literature. The review covers molecular pathway analysis including secretase regulation, mitochondrial function, autophagy, and neuroinflammatory signaling.
Study Limitations
The evidence base is predominantly preclinical, with limited robust human clinical trial data supporting efficacy in AD patients. Bioavailability in the human brain remains a challenge, though nanoformulation approaches show early promise. Optimal dosing, long-term safety, and drug interaction profiles in aging populations require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.